Oncternal Therapeutics (ONCT) investor relations material

Executive summary

• Discontinued all clinical trials and product development activities as of September 12, 2024, to explore strategic alternatives including asset sales, licensing, or business combinations.

• Initiated a reduction-in-force in September 2024 and will continue to assess further cost reduction measures.

• Focused on maximizing stockholder value through potential transactions; no assurance of successful outcomes.

Financial highlights

• Net loss of $8.5 million for Q3 2024, compared to $9.9 million in Q3 2023; net loss of $25.4 million for the nine months ended September 30, 2024, versus $30.3 million in the prior year period.

• Grant revenue was $0.5 million for Q3 2024 and $1.9 million for the nine months ended September 30, 2024, up from $0.2 million and $0.5 million, respectively, in 2023.

• Research and development expenses decreased to $6.4 million in Q3 2024 from $7.5 million in Q3 2023; nine-month R&D expenses were $19.1 million, down from $23.1 million.

• General and administrative expenses were $2.7 million in Q3 2024, down from $3.1 million in Q3 2023; nine-month G&A expenses were $9.1 million, down from $9.5 million.

• Cash, cash equivalents, and short-term investments totaled $14.6 million as of September 30, 2024, with no debt.

Outlook and guidance

• Research and development expenses are expected to decrease significantly as clinical activities are discontinued, with ongoing costs related to trial closures and nonclinical projects.

• Management concluded that current cash resources are sufficient to fund operations into Q1 2025, but not for the full twelve months following the report date without additional funding or asset sales.

• There is substantial doubt about the company's ability to continue as a going concern for twelve months following the report date.